The tumor microenvironment (TME) is characterized by elevated glutathione (GSH) levels and hypoxia, two interrelated pathological features that synergistically contribute to radioresistance. Conventional nanozymes, however, are constrained by intrinsically low catalytic efficiency, limited functional versatility, and inadequate biocompatibility, key limitations that collectively hinder their clinical translation. To overcome these barriers, we developed a hyaluronic acid-modified Pt@MnO 2 -Au-HA nanozyme with a well-defined core–shell–satellite architecture: a platinum (Pt) core, a conformal MnO 2 interlayer, and spatially controlled gold (Au) nanoparticle satellites. Following intravenous administration, Pt@MnO 2 -Au-HA selectively targets proinflammatory macrophages in the tumor microenvironment via hyaluronic acid–mediated CD44 receptor recognition. Within the tumor, endogenously overexpressed hydrogen peroxide (H 2 O 2 ) is catalytically decomposed into oxygen (O 2 ) by the MnO 2 component, which exhibits intrinsic catalase (CAT)-like activity. This O 2 generation serves as an endogenous oxygen source to enhance glucose depletion via the glucose oxidase (GOx)-like activity of the Au component, thereby enabling starvation therapy. Concurrently, elevated intratumoral GSH induces the reductive dissolution of MnO 2 , resulting in both GSH consumption and controlled release of the Pt core. The liberated Pt nanoparticles further exert CAT-like activity to convert H 2 O 2 into O 2 , effectively alleviating tumor hypoxia and synergistically amplifying radiotherapy efficacy through enhanced radiosensitization.